Clinical Study
June 11, 2025
Capricor Therapeutics, a biotechnology company focused on developing innovative cell and exosome-based therapeutics for rare diseases, has announced significant regulatory progress for its Duchenne Muscular Dystrophy (DMD) program. The company report...
|
Clinical Study
Clinical Study
June 11, 2025
In an exciting development in the realm of mental health therapeutics, Silo Pharma, Inc. (Nasdaq: SILO) has made significant strides toward advancing its innovative PTSD treatment, SPC-15. Silo Pharma recently announced that the U.S. Patent and Trade...
|
Clinical Study
June 11, 2025
Osteoarthritis (OA) is a progressive degenerative disease characterized by the breakdown of cartilage and underlying bone, leading to significant pain and functional limitations. The potential for gene therapy to offer a durable solution for managin...
|
Clinical Study
June 9, 2025
Presented by CSIMarket.com In a groundbreaking presentation at the BBA 2025, AVITA Medical showcased the largest real-world analysis of its RECELL system, highlighting its potential to revolutionize inpatient burn care. Combining technological inn...
|
|
Clinical Study
June 9, 2025
Presented by CSIMarket.com In a groundbreaking presentation at the BBA 2025, AVITA Medical showcased the largest real-world analysis of its RECELL system, highlighting its potential to revolutionize inpatient burn care. Combining technological inn...
Clinical Study
June 3, 2025
In the rapidly evolving landscape of oncology treatment, Kura Oncology Inc. in collaboration with Kyowa Kirin Co. is making significant strides with its pioneering drug, ziftomenib. At the prestigious 2025 ASCO Annual Meeting, the announcement of pos...
|
Clinical Study
June 2, 2025
At the recent American Society of Clinical Oncology (ASCO) 2025 meeting, Cardiff Oncology presented promising results from an investigator-initiated Phase 1b clinical trial evaluating the combination of onvansertib and paclitaxel in patients with met...
|
Clinical Study
June 2, 2025
In a recent Investor and Analyst Day, Rapport Therapeutics made noteworthy strides in its ongoing commitment to advancing treatments for neurological disorders, particularly refractory focal epilepsy. The company announced that it has successfully en...
|
Clinical Study
June 2, 2025
Pioneering Advances in Bradykinin-Mediated Angioedema: Pharvaris Unveils Promising Data on DeucrictibantIn a significant stride towards addressing the unmet medical needs of patients with bradykinin-mediated disorders, Pharvaris, a late-stage biopha...
|
Clinical Study
May 31, 2025
In a groundbreaking presentation at Psych Congress Elevate 2025, Teva Pharmaceuticals has unveiled new data revealing significant rates of undertreated tardive dyskinesia (TD) among patients in long-term care (LTC) settings. This announcement is part...
|
Our most popular articles about Clinical Study
Clinical Study
October 3, 2024
In recent developments, Barinthus Biotherapeutics plc (NASDAQ: BRNS), a pioneering clinical-stage biopharmaceutical firm, has made significant strides in its clinical programs targeting chronic hepatitis B (CHB) and prostate cancer. Notably, the com...
|
Clinical Study
May 23, 2024
Candel Therapeutics, a clinical stage biopharmaceutical company, has recently made significant advancements in the development of multimodal biological immunotherapies to combat cancer. The company s innovative approach aims to address the limitation...
|
Clinical Study
October 5, 2024
Title : Unlocking Hope: BioCryst Pharmaceuticals? Groundbreaking Step Towards Treating Netherton Syndrome with BCX17725 :In the realm of rare genetic disorders, Netherton syndrome looms with its complex tapestry of symptoms, including severe skin ma...
|
Clinical Study
October 25, 2024
Microbot Medical, a pioneering company in the field of minimally invasive robotic technologies, has announced the successful completion of its pivotal human clinical trial for the LIBERTY system. This promising development not only signifies a crucia...
|
Recently Published News |
Clinical Study
May 24, 2025
Immunotherapy Advances: SYNC-T for Prostate Cancer and Merus for Head and Neck Cancer In recent developments in cancer therapeutics, innovative immunotherapy treatments have shown promising efficacy, highlighting a transformative era in managing met...
|
Clinical Study
May 23, 2025
At the 2025 ASCO Annual Meeting, Biodesix announced significant discoveries from their INSIGHT study, emphasizing the predictive capabilities of the VeriStrat Host Immune Classifier (HIC) in assessing overall survival outcomes for patients with non-s...
|
Clinical Study
May 23, 2025
Promising Advances in Relapsed/Refractory Multiple Myeloma Treatment: Linvoseltamab Combined with Carfilzomib or Bortezomib Shows Encouraging ResultsIn a significant development for multiple myeloma patients, early results from clinical studies indi...
|
Clinical Study
May 23, 2025
Paving the Path in Oncology: Zymeworks Sets the Stage for Medical Breakthroughs at Premier Global Conferences In an inspiring move set to influence the oncology landscape significantly, Zymeworks Inc. (Nasdaq: ZYME) is gearing up to highlight its in...
|
Clinical Study
May 23, 2025
In a landmark achievement recently reported by Gyre Therapeutics Inc. (NASDAQ: GYRE), the company s lead candidate, Hydronidone, has successfully met its primary endpoint in a pivotal Phase 3 trial aimed at treating chronic hepatitis B (CHB)-associat...
|
Clinical Study
May 21, 2025
Belite Bio s Breakthrough in the Treatment of Stargardt DiseaseBelite Bio Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical company, has recently been thrust into the spotlight with the announcement that the U.S. Food and Drug Administration (...
|
Clinical Study
May 20, 2025
Potential Therapeutic Advances: Preclinical Insights into ZW1528, a Novel IL4R x IL33 Bispecific Molecule for Respiratory Inflammation Biotherapeutics have revolutionized the treatment landscape for numerous diseases, offering targeted approaches th...
|
Clinical Study
May 19, 2025
BiomX Inc. a clinical-stage company specializing in phage therapy, continues to make strides in developing innovative treatments targeting pathogenic bacteria associated with chronic diseases. This article outlines the recent advancements seen in B...
|
Clinical Study
May 18, 2025
Tectonic Therapeutic, Inc. (NASDAQ: TECX) recently shared the complete results from Part A of their Phase 1b clinical trial of TX45, a potential treatment for Group 2 Pulmonary Hypertension in patients with Heart Failure with preserved Ejection Fract...
|
Clinical Study
May 15, 2025
Acute Myeloid Leukemia (AML) is a severe hematologic malignancy impacting both adults and children. The pediatric variant of AML tends to have unique genetic features and treatment challenges. Recent progress in targeted therapies and personalized me...
|
Clinical Study
May 11, 2025
Shuttle Pharmaceuticals Approaches Milestone in Phase 2 Clinical Trial for Ropidoxuridine in Glioblastoma Treatment Shuttle Pharmaceuticals Holdings, Inc. a pioneering player in the specialty pharmaceutical sector, has announced significant progress...
|
Clinical Study
May 11, 2025
Corvus Pharmaceuticals has recently announced favorable data from the first three cohorts of its placebo-controlled Phase 1 clinical trial of Soquelitinib, targeting atopic dermatitis. These findings are detailed amidst the company s latest financia...
|
Clinical Study
May 11, 2025
Recent presentations by Akero Therapeutics and HistoIndex at the 2025 EASL Congress have brought forward significant advancements in the understanding and assessment of liver fibrosis, specifically in the context of the Phase 2b HARMONY trial. Util...
|
Clinical Study
May 9, 2025
Targeting Dry AMD: Cognition Therapeutics Unveils Promising Preclinical Data on Zervimesine for Retinal Cell HealthIn a significant advancement in the ongoing battle against neurodegenerative disorders, Cognition Therapeutics, Inc. (NASDAQ: CGTX), a...
|
Clinical Study
May 9, 2025
Akero Therapeutics Pushes Boundaries in Cirrhosis Treatment: Updates from SYMMETRY and SYNCHRONY Trials In an era where the implications of metabolic liver diseases are becoming increasingly pressing, Akero Therapeutics, a clinical-stage biopharmac...
|
Clinical Study
May 9, 2025
In the realm of ophthalmology, the continual quest for innovative treatments to address macular diseases has garnered significant attention, and Clearside Biomedical Inc. stands at the forefront of this endeavour. At the prestigious Association for R...
|
Clinical Study
May 9, 2025
Promising Developments in Alzheimer s Treatment: Tiziana Life Sciences Intranasal Foralumab Shows Significant Reduction in Microglia ActivationTiziana Life Sciences, a biotechnology company known for its innovative therapeutic approaches, has annou...
|
Clinical Study
May 1, 2025
In a notable development for the biopharmaceutical sector, Bio-Path Holdings, Inc. (NASDAQ: BPTH) has announced it has achieved its third pre-clinical milestone in its efforts to advance BP1001-A, a promising treatment aimed at tackling obesity, part...
|
Clinical Study
May 1, 2025
Atea Pharmaceuticals Inc. is poised to illuminate the ongoing challenges faced by patients with Hepatitis C Virus (HCV) through an engaging virtual Key Opinion Leader (KOL) panel scheduled for May 14, 2025. This crucial dialogue will delve into the l...
|
Clinical Study
April 30, 2025
Unlocking Cardiovascular Breakthroughs: NewAmsterdam Pharma s Promising DevelopmentsNewAmsterdam Pharma, a late-stage clinical biopharmaceutical company, has captured the attention of the scientific community with its recent data presentations at th...
|
Clinical Study
April 30, 2025
Overview of NBTXR3 Phase 1 Study in Pancreatic CancerNanobiotix, a late-clinical stage biotechnology company, has recently announced the completion of its Phase 1 study evaluating JNJ-1900, also known as NBTXR3, in patients with locally advanced pa...
|
Clinical Study
April 29, 2025
Atossa Therapeutics Proposes Groundbreaking Clinical Study to Address Interval Breast Cancer in High-Risk Women: Insights from the AACR 2025 Meeting April 29, 2025 - In an exciting development for the future of breast cancer prevention, Atossa Therap...
|
Clinical Study
April 29, 2025
Artiva Biotherapeutics, Inc. is poised to make a significant impact in the fight against B-cell non-Hodgkin lymphoma (NHL) through its innovative therapy, AlloNK, combined with the monoclonal antibody rituximab. At the upcoming 28th Annual Meeting of...
|
Clinical Study
April 29, 2025
Pioneering Advances in Cell Therapy: Century Therapeutics at the Forefront of InnovationIn a landscape where pioneering science meets unmet clinical needs, Century Therapeutics, Inc. a notable player in biotechnology, has become a significant torchb...
|
Clinical Study
April 29, 2025
CAMP4 Therapeutics is set to highlight new preclinical data from its innovative Urea Cycle Disorders and SYNGAP1-Related Disorders programs at the upcoming 28th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. The presentation is exp...
|
Clinical Study
April 29, 2025
Sutro Biopharma has emerged as a front-runner in the development of innovative cancer therapies. At the upcoming American Association for Cancer Research (AACR) 2025 conference, the company will unveil preclinical findings for its lead candidate, STR...
|
Clinical Study
April 28, 2025
In a recent press release, Foghorn Therapeutics shared compelling preclinical data about their innovative endeavors in cancer therapy development. The company has made significant expansions in its pipeline, focusing on the promising capabilities of ...
|
Clinical Study
April 26, 2025
: The evolving landscape of melanoma diagnosis and management continues to demand innovative tools for precise risk stratification, particularly for early-stage patients. Recent presentations at the AACR Annual Meeting 2025 underscore the promising ...
|
Clinical Study
April 25, 2025
Myriad Genetics: Unveiling Clinical Validity of Precise MRD at AACR Annual MeetingIn an era where precision medicine is increasingly guiding therapeutic decisions, Myriad Genetics continues to make impressive strides. The company recently highlighte...
|
Clinical Study
April 25, 2025
Prelude Therapeutics Inc: A New Chapter in Targeted Cancer Therapies Amid Financial Challenges and Promising Preclinical Data Prelude Therapeutics Inc, a biotechnology company dedicated to transforming the treatment landscape for patients with cancer...
|
Clinical Study
April 25, 2025
: The field of oncology is rapidly evolving with the development of new and innovative treatments. Pyxis Oncology is at the forefront, presenting promising preclinical results for its first-in-concept extracellular-targeting antibody-drug conjugate...
|
Clinical Study
April 25, 2025
Factual Olema Oncology, a clinical-stage biopharmaceutical company specialized in developing targeted therapies for breast cancer and other malignancies, has announced significant preclinical findings regarding its investigational drug OP-3136. The ...
|
Clinical Study
April 25, 2025
: At the 2025 Annual Meeting of the American Association for Cancer Research (AACR), Bolt Biotherapeutics unveiled promising results from their Phase 1 dose-escalation clinical trial of BDC-3042. This investigational therapy shows notable potential...
|
Clinical Study
April 25, 2025
Nurix Therapeutics Unveils Groundbreaking Preclinical Data at AACR 2025: Orally Available Degraders Show Promise Against Key Oncology TargetsIn an exciting development set to transform the landscape of oncology treatment, Nurix Therapeutics recently...
|
Clinical Study
April 24, 2025
Aligos Therapeutics Sets Stage for EASL Congress 2025 with Eight Accepted s SOUTH SAN FRANCISCO, Calif. April 23, 2025 Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical-stage biopharmaceutical company dedicated to enhancing patient outcomes thro...
|
Clinical Study
April 22, 2025
Lipella Pharmaceuticals Advances in Oral Lichen Planus Treatment and Bladder Imaging Technology Lipella Pharmaceuticals, a pioneering biopharmaceutical company, has announced significant advancements in its clinical trials and imaging techniques, pos...
|
Clinical Study
April 21, 2025
In recent weeks, Achieve Life Sciences Inc. has garnered attention following the publication of its Phase 3 ORCA-3 trial results on cytisinicline, a potential new tool for smoking cessation. The findings, published in JAMA Internal Medicine, highligh...
|
Clinical Study
April 15, 2025
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy Designation for LYL314 in Overcoming Persistent Large B-Cell Lymphoma South San Francisco, California April 15, 2025 Lyell Immunopharma, Inc. (Nasdaq: LYEL), a leader in the clinic...
|
Clinical Study
April 12, 2025
Innovative Advances in Gene Editing: Verve Therapeutics VERVE-102 in Hyperlipidemia Treatment Cardiovascular disease continues to be a leading cause of morbidity and mortality worldwide. As such, innovative treatment strategies targeting the underl...
|
Clinical Study
April 12, 2025
In an important development for the field of regenerative medicine, FibroBiologics, Inc. a clinical-stage biotechnology company, has announced its participation in The Cell & Gene Meeting on the Mediterranean, taking place from April 15-17, 2025, in ...
|
Clinical Study
April 11, 2025
BioCardia, Inc. (Nasdaq: BCDA), a frontrunner in cellular and cell-derived therapeutics aimed at addressing cardiovascular and pulmonary diseases, continues to make significant strides in the field of cardiac care. The company recently announced the ...
|
Clinical Study
April 10, 2025
: Gain Therapeutics, Inc. (NASDAQ: GANX) has garnered attention at the AD/PD 2025 conference with its recent oral presentation on the promising preclinical data of GT-02287. The data highlights the disease-modifying potential of this investigational ...
|
|
|
|
News |
Clinical Study
June 12, 2025
'Abstract' Third Harmonic Bio Inc. (THB) has recently undergone significant corporate transformations, including stockholder-approved liquidation and dissolution. Meanwhile, financial ratios reveal a dynamic yet challenging fiscal environment. This ...
|
Clinical Study
June 12, 2025
In a significant stride for the field of nuclear medicine, Lantheus Holdings, Inc., a leading radiopharmaceutical company, has announced the presentation of promising new data at the upcoming 2025 Society of Nuclear Medicine and Molecular Imaging (SN...
|
Stock Market
Clinical Study
June 12, 2025
Breakthrough Developments in Lupus and Kidney Transplant Treatments: Dapirolizumab Pegol and Felzartamab Lead the WayIn recent pivotal advancements within the field of immunology, Biogen Inc. (NASDAQ: BIIB) and UCB (Euronext Brussels: UCB) have demo...
|
Clinical Study
June 3, 2025
In the rapidly evolving landscape of oncology treatment, Kura Oncology Inc. in collaboration with Kyowa Kirin Co. is making significant strides with its pioneering drug, ziftomenib. At the prestigious 2025 ASCO Annual Meeting, the announcement of pos...
|
Our most popular articles about Clinical Study
Clinical Study
October 25, 2024
Microbot Medical, a pioneering company in the field of minimally invasive robotic technologies, has announced the successful completion of its pivotal human clinical trial for the LIBERTY system. This promising development not only signifies a crucia...
|
Clinical Study
October 24, 2024
Dementia with Lewy bodies (DLB), a progressive neurodegenerative disorder, presents a considerable challenge in the realm of medical research and treatment, primarily due to its complex pathology and overlapping symptoms with Alzheimer s and Parkinso...
|
Clinical Study
May 29, 2024
TScan Therapeutics Receives FDA s RMAT Designation for Pioneering TCR-T Therapy Candidates TSC-100 and TSC-101 A Promising Leap Forward in the Treatment of Hematologic MalignanciesTScan Therapeutics has achieved a significant milestone with the U.S....
|
Clinical Study
June 2, 2025
At the recent American Society of Clinical Oncology (ASCO) 2025 meeting, Cardiff Oncology presented promising results from an investigator-initiated Phase 1b clinical trial evaluating the combination of onvansertib and paclitaxel in patients with met...
|
Clinical Study
June 2, 2025
In a recent Investor and Analyst Day, Rapport Therapeutics made noteworthy strides in its ongoing commitment to advancing treatments for neurological disorders, particularly refractory focal epilepsy. The company announced that it has successfully en...
|
Clinical Study
June 2, 2025
Pioneering Advances in Bradykinin-Mediated Angioedema: Pharvaris Unveils Promising Data on DeucrictibantIn a significant stride towards addressing the unmet medical needs of patients with bradykinin-mediated disorders, Pharvaris, a late-stage biopha...
|
Clinical Study
May 31, 2025
In a groundbreaking presentation at Psych Congress Elevate 2025, Teva Pharmaceuticals has unveiled new data revealing significant rates of undertreated tardive dyskinesia (TD) among patients in long-term care (LTC) settings. This announcement is part...
|
Clinical Study
May 31, 2025
Kymera Therapeutics, a biotechnology company focused on innovative therapeutics, is poised to share crucial updates about its lead product candidate, KT-621, with the upcoming announcement of Phase 1 trial results. Scheduled for June 2, 2025, at 8:00...
|
Clinical Study
May 27, 2025
In the evolving landscape of biopharmaceutical innovation, Vaccinex Inc. has emerged as a key player with its investigational drug pepinemab, a monoclonal antibody showing great potential in treating both head and neck cancer as well as Alzheimer s d...
|
Clinical Study
May 27, 2025
Charting Uncharted Waters: Ocugen s Ground-breaking Endeavours in Stargardt Disease Treatment In a realm where hope often flickers amidst shadow, Ocugen Inc. a luminary in the field of biotechnology, emerges as a beacon of promise for those navigati...
|
Clinical Study
May 27, 2025
Exploring the Therapeutic Potential of SER-155: Insights from Biomarker Data and Economic Challenges of Seres Therapeutics The landscape of post-transplant care has continuously evolved, with recent advancements focusing on enhancing immune recovery...
|
Clinical Study
May 24, 2025
Immunotherapy Advances: SYNC-T for Prostate Cancer and Merus for Head and Neck Cancer In recent developments in cancer therapeutics, innovative immunotherapy treatments have shown promising efficacy, highlighting a transformative era in managing met...
|
Clinical Study
May 23, 2025
At the 2025 ASCO Annual Meeting, Biodesix announced significant discoveries from their INSIGHT study, emphasizing the predictive capabilities of the VeriStrat Host Immune Classifier (HIC) in assessing overall survival outcomes for patients with non-s...
|
Clinical Study
May 23, 2025
Promising Advances in Relapsed/Refractory Multiple Myeloma Treatment: Linvoseltamab Combined with Carfilzomib or Bortezomib Shows Encouraging ResultsIn a significant development for multiple myeloma patients, early results from clinical studies indi...
|
Clinical Study
May 23, 2025
Paving the Path in Oncology: Zymeworks Sets the Stage for Medical Breakthroughs at Premier Global Conferences In an inspiring move set to influence the oncology landscape significantly, Zymeworks Inc. (Nasdaq: ZYME) is gearing up to highlight its in...
|
Clinical Study
May 23, 2025
In a landmark achievement recently reported by Gyre Therapeutics Inc. (NASDAQ: GYRE), the company s lead candidate, Hydronidone, has successfully met its primary endpoint in a pivotal Phase 3 trial aimed at treating chronic hepatitis B (CHB)-associat...
|
Clinical Study
May 21, 2025
Belite Bio s Breakthrough in the Treatment of Stargardt DiseaseBelite Bio Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical company, has recently been thrust into the spotlight with the announcement that the U.S. Food and Drug Administration (...
|
Clinical Study
May 20, 2025
Potential Therapeutic Advances: Preclinical Insights into ZW1528, a Novel IL4R x IL33 Bispecific Molecule for Respiratory Inflammation Biotherapeutics have revolutionized the treatment landscape for numerous diseases, offering targeted approaches th...
|
Clinical Study
May 19, 2025
BiomX Inc. a clinical-stage company specializing in phage therapy, continues to make strides in developing innovative treatments targeting pathogenic bacteria associated with chronic diseases. This article outlines the recent advancements seen in B...
|
Clinical Study
May 18, 2025
Tectonic Therapeutic, Inc. (NASDAQ: TECX) recently shared the complete results from Part A of their Phase 1b clinical trial of TX45, a potential treatment for Group 2 Pulmonary Hypertension in patients with Heart Failure with preserved Ejection Fract...
|
Clinical Study
May 15, 2025
Acute Myeloid Leukemia (AML) is a severe hematologic malignancy impacting both adults and children. The pediatric variant of AML tends to have unique genetic features and treatment challenges. Recent progress in targeted therapies and personalized me...
|
Clinical Study
May 11, 2025
Shuttle Pharmaceuticals Approaches Milestone in Phase 2 Clinical Trial for Ropidoxuridine in Glioblastoma Treatment Shuttle Pharmaceuticals Holdings, Inc. a pioneering player in the specialty pharmaceutical sector, has announced significant progress...
|
Clinical Study
May 11, 2025
Corvus Pharmaceuticals has recently announced favorable data from the first three cohorts of its placebo-controlled Phase 1 clinical trial of Soquelitinib, targeting atopic dermatitis. These findings are detailed amidst the company s latest financia...
|
Clinical Study
May 11, 2025
Recent presentations by Akero Therapeutics and HistoIndex at the 2025 EASL Congress have brought forward significant advancements in the understanding and assessment of liver fibrosis, specifically in the context of the Phase 2b HARMONY trial. Util...
|
Clinical Study
May 9, 2025
Targeting Dry AMD: Cognition Therapeutics Unveils Promising Preclinical Data on Zervimesine for Retinal Cell HealthIn a significant advancement in the ongoing battle against neurodegenerative disorders, Cognition Therapeutics, Inc. (NASDAQ: CGTX), a...
|
Clinical Study
May 9, 2025
Akero Therapeutics Pushes Boundaries in Cirrhosis Treatment: Updates from SYMMETRY and SYNCHRONY Trials In an era where the implications of metabolic liver diseases are becoming increasingly pressing, Akero Therapeutics, a clinical-stage biopharmac...
|
Clinical Study
May 9, 2025
In the realm of ophthalmology, the continual quest for innovative treatments to address macular diseases has garnered significant attention, and Clearside Biomedical Inc. stands at the forefront of this endeavour. At the prestigious Association for R...
|
Clinical Study
May 9, 2025
Promising Developments in Alzheimer s Treatment: Tiziana Life Sciences Intranasal Foralumab Shows Significant Reduction in Microglia ActivationTiziana Life Sciences, a biotechnology company known for its innovative therapeutic approaches, has annou...
|
Clinical Study
May 1, 2025
In a notable development for the biopharmaceutical sector, Bio-Path Holdings, Inc. (NASDAQ: BPTH) has announced it has achieved its third pre-clinical milestone in its efforts to advance BP1001-A, a promising treatment aimed at tackling obesity, part...
|
Clinical Study
May 1, 2025
Atea Pharmaceuticals Inc. is poised to illuminate the ongoing challenges faced by patients with Hepatitis C Virus (HCV) through an engaging virtual Key Opinion Leader (KOL) panel scheduled for May 14, 2025. This crucial dialogue will delve into the l...
|
Clinical Study
April 30, 2025
Unlocking Cardiovascular Breakthroughs: NewAmsterdam Pharma s Promising DevelopmentsNewAmsterdam Pharma, a late-stage clinical biopharmaceutical company, has captured the attention of the scientific community with its recent data presentations at th...
|
Clinical Study
April 30, 2025
Overview of NBTXR3 Phase 1 Study in Pancreatic CancerNanobiotix, a late-clinical stage biotechnology company, has recently announced the completion of its Phase 1 study evaluating JNJ-1900, also known as NBTXR3, in patients with locally advanced pa...
|
Clinical Study
April 29, 2025
Atossa Therapeutics Proposes Groundbreaking Clinical Study to Address Interval Breast Cancer in High-Risk Women: Insights from the AACR 2025 Meeting April 29, 2025 - In an exciting development for the future of breast cancer prevention, Atossa Therap...
|
Clinical Study
April 29, 2025
Artiva Biotherapeutics, Inc. is poised to make a significant impact in the fight against B-cell non-Hodgkin lymphoma (NHL) through its innovative therapy, AlloNK, combined with the monoclonal antibody rituximab. At the upcoming 28th Annual Meeting of...
|
Clinical Study
April 29, 2025
Pioneering Advances in Cell Therapy: Century Therapeutics at the Forefront of InnovationIn a landscape where pioneering science meets unmet clinical needs, Century Therapeutics, Inc. a notable player in biotechnology, has become a significant torchb...
|
Clinical Study
April 29, 2025
CAMP4 Therapeutics is set to highlight new preclinical data from its innovative Urea Cycle Disorders and SYNGAP1-Related Disorders programs at the upcoming 28th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. The presentation is exp...
|
Clinical Study
April 29, 2025
Sutro Biopharma has emerged as a front-runner in the development of innovative cancer therapies. At the upcoming American Association for Cancer Research (AACR) 2025 conference, the company will unveil preclinical findings for its lead candidate, STR...
|
Clinical Study
April 28, 2025
In a recent press release, Foghorn Therapeutics shared compelling preclinical data about their innovative endeavors in cancer therapy development. The company has made significant expansions in its pipeline, focusing on the promising capabilities of ...
|
Clinical Study
April 26, 2025
: The evolving landscape of melanoma diagnosis and management continues to demand innovative tools for precise risk stratification, particularly for early-stage patients. Recent presentations at the AACR Annual Meeting 2025 underscore the promising ...
|
Clinical Study
April 25, 2025
Myriad Genetics: Unveiling Clinical Validity of Precise MRD at AACR Annual MeetingIn an era where precision medicine is increasingly guiding therapeutic decisions, Myriad Genetics continues to make impressive strides. The company recently highlighte...
|
Clinical Study
April 25, 2025
Prelude Therapeutics Inc: A New Chapter in Targeted Cancer Therapies Amid Financial Challenges and Promising Preclinical Data Prelude Therapeutics Inc, a biotechnology company dedicated to transforming the treatment landscape for patients with cancer...
|
Clinical Study
April 25, 2025
: The field of oncology is rapidly evolving with the development of new and innovative treatments. Pyxis Oncology is at the forefront, presenting promising preclinical results for its first-in-concept extracellular-targeting antibody-drug conjugate...
|
Clinical Study
April 25, 2025
Factual Olema Oncology, a clinical-stage biopharmaceutical company specialized in developing targeted therapies for breast cancer and other malignancies, has announced significant preclinical findings regarding its investigational drug OP-3136. The ...
|
Clinical Study
April 25, 2025
: At the 2025 Annual Meeting of the American Association for Cancer Research (AACR), Bolt Biotherapeutics unveiled promising results from their Phase 1 dose-escalation clinical trial of BDC-3042. This investigational therapy shows notable potential...
|
Clinical Study
April 25, 2025
Nurix Therapeutics Unveils Groundbreaking Preclinical Data at AACR 2025: Orally Available Degraders Show Promise Against Key Oncology TargetsIn an exciting development set to transform the landscape of oncology treatment, Nurix Therapeutics recently...
|
Clinical Study
April 24, 2025
Aligos Therapeutics Sets Stage for EASL Congress 2025 with Eight Accepted s SOUTH SAN FRANCISCO, Calif. April 23, 2025 Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical-stage biopharmaceutical company dedicated to enhancing patient outcomes thro...
|
Clinical Study
April 22, 2025
Lipella Pharmaceuticals Advances in Oral Lichen Planus Treatment and Bladder Imaging Technology Lipella Pharmaceuticals, a pioneering biopharmaceutical company, has announced significant advancements in its clinical trials and imaging techniques, pos...
|
Clinical Study
April 21, 2025
In recent weeks, Achieve Life Sciences Inc. has garnered attention following the publication of its Phase 3 ORCA-3 trial results on cytisinicline, a potential new tool for smoking cessation. The findings, published in JAMA Internal Medicine, highligh...
|
Clinical Study
April 15, 2025
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy Designation for LYL314 in Overcoming Persistent Large B-Cell Lymphoma South San Francisco, California April 15, 2025 Lyell Immunopharma, Inc. (Nasdaq: LYEL), a leader in the clinic...
|
Clinical Study
April 12, 2025
Innovative Advances in Gene Editing: Verve Therapeutics VERVE-102 in Hyperlipidemia Treatment Cardiovascular disease continues to be a leading cause of morbidity and mortality worldwide. As such, innovative treatment strategies targeting the underl...
|
Clinical Study
April 12, 2025
In an important development for the field of regenerative medicine, FibroBiologics, Inc. a clinical-stage biotechnology company, has announced its participation in The Cell & Gene Meeting on the Mediterranean, taking place from April 15-17, 2025, in ...
|
Clinical Study
April 11, 2025
BioCardia, Inc. (Nasdaq: BCDA), a frontrunner in cellular and cell-derived therapeutics aimed at addressing cardiovascular and pulmonary diseases, continues to make significant strides in the field of cardiac care. The company recently announced the ...
|
Clinical Study
April 10, 2025
: Gain Therapeutics, Inc. (NASDAQ: GANX) has garnered attention at the AD/PD 2025 conference with its recent oral presentation on the promising preclinical data of GT-02287. The data highlights the disease-modifying potential of this investigational ...
|
Clinical Study
April 9, 2025
The realm of neurodegenerative and psychiatric disorders has long been challenging for researchers and clinicians alike. Recently, a notable advancement was made by Cerevance, a clinical-stage biopharmaceutical company, which unveiled promising resu...
|
Clinical Study
April 9, 2025
In an era marked by significant advancements in antiviral therapy, Assembly Biosciences has unveiled pivotal data at the 2025 European Congress of Clinical Microbiology and Infectious Diseases (ESCMID) that could reshape our understanding and managem...
|
Clinical Study
April 9, 2025
The landscape of drug development in neurodegenerative diseases is continually evolving, marked by innovative approaches such as the Expanded Access Program (EAP). This article analyzes the recent enrollment of the first patient in an EAP trial eval...
|
Clinical Study
April 8, 2025
: This article summarises pivotal Phase 3 data presented by Annexon at the American Academy of Neurology?s 2025 Annual Meeting, reinforcing the potential of Tanruprubart (formerly ANX005) as a targeted therapy for Guillain-Barré Syndrome (GBS). Insi...
|
Clinical Study
April 7, 2025
Revolutionizing Muscle Regeneration: iBio s Groundbreaking Advances in Anti-Myostatin Antibody Therapy The biotechnology landscape is on the cusp of a significant evolution, heralded by promising advancements from iBio, Inc. a pioneering bio-pharmace...
|
|
|
|
|
|
